Third antigen's a charm: Gilead pens deal with Merus for up to three trispecific antibodies
Gilead has enlisted Merus in a research deal to develop new trispecific antibodies that can harness the immune system to fight cancer.
Merus will receive $56 million upfront plus a $25 million investment from Gilead. In exchange, Merus will conduct early-stage research on two trispecific antibody programs, with an option for a third. Gilead has the right to license the programs from Merus after early research, after which Gilead will be responsible for additional R&D and commercialization for the programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
